Regeneron | search
Click here to view Regeneron news from 60+ newspapers.
Bookmark or Share- Regeneron Pharmaceuticals: Delivering Life-transforming MedicinesRegeneron (NASDAQ: REGN) is a leading biotechnology company using the power of science to bring new medicines to patients in need. Learn more.
- INVESTORS & MEDIA - Regeneron Pharmaceuticals Inc.Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) updated the Emergency Use Authorization (EUA) for the investigational COVID-19 antibody cocktail REGEN-COV™ (casirivimab and imdevimab). The authorization now includes post-exposure prophylaxis in people at high risk for progression ...
- Regeneron Pharmaceuticals - WikipediaRegeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. [2] Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase ...
- About Regeneron Pharmaceuticals: Innovative BiotechnologyReinventing Drug Discovery. For 35 years, our mission has been to use the power of science to bring new medicines to patients… over and over again. Regeneron is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases.
- INVESTORS & MEDIA - Regeneron Pharmaceuticals Inc.This definitive Phase 3 outcomes trial in high-risk non-hospitalized COVID-19 patients ("outpatients") met its primary endpoint, showing the investigational REGEN-COV™ (casirivimab with imdevimab) significantly reduced the risk of hospitalization or death by 70% (1,200 mg intravenous [IV]) and 71% (2,400 mg IV) compared to placebo.
More
